Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseEssential ThrombocythemiaSubgroupalso in pregnancyICD10D47.3MeSHThrombocythemia, EssentialSequenceChemotherapyChemo-substanceAnagrelideHydroxyureaInterferon alpha-2a pegylatedRuxolitinibChemo-substanceAnagrelideHydroxyureaInterferon alpha-2a pegylatedRuxolitinibChemo-substanceAnagrelideHydroxyureaInterferon alpha-2a pegylatedRuxolitinibChemo-substanceAnagrelideHydroxyureaInterferon alpha-2a pegylatedRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineThird line Therapy phaseTherapy intentiondisease controlRisksAbdominal PainCardiotoxicityDepressionDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)HeadacheHypertensionInfectionsNeutropeniaPalpitationsTachycardiaThromboembolic Event only studiesPublicationAuthorGisslinger HHarrison CQuinta´s-Cardama, A.Diseaseessentielle Thrombozythämie, nach WHO KlassifikationEssentielle Thrombozythämie, neu diagnostiziert oder vorbehandeltHochrisiko ET oder PV, intolerant oder resistent gegen HydroxyureaOriginDepartments of Leukemia and Hematopathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.Guy´s and St. Thomas NHS Foundation Trust, London, UKMedical University of Vienna, Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Vienna, Austria, ANAHYDRET StudyProtocols in Revision 4 protocols foundProtocols under revision.Anagrelide 0.5, Essential Thrombocythemia (PID1218 V1.0)Hydroxyurea 20, Essential Thrombocythemia (PID8 V1.0)Peginterferon alpha-2a 90, Essential Thrombocythemia (PID1217 V1.0)Ruxolitinib 25, Essential Thrombocythemia (PID924 V1.0)
